Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Background The sodium‐glucose cotransporter 2 inhibitor canagliflozin reduced the risk of first cardiovascular composite events in the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. In this post hoc analysis, we evaluated the effect of c...

Full description

Bibliographic Details
Main Authors: Jing‐Wei Li, Clare Arnott, Hiddo J. L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler, David M. Charytan, Jennifer Barraclough, Gemma A. Figtree, Rajiv Agarwal, George Bakris, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Meg J. Jardine
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
canagliflozin
chronic kidney disease
diabetes
recurrent cardiovascular event
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.025045

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.025045

Similar Items